Published in Tumour Biol on April 21, 2016
ING5 knockdown enhances migration and invasion of lung cancer cells by inducing EMT via EGFR/PI3K/Akt and IL-6/STAT3 signaling pathways. Oncotarget (2017) 0.75
EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells. Cell Oncol (Dordr) (2017) 0.75
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer (2002) 28.11
Eph-ephrin bidirectional signaling in physiology and disease. Cell (2008) 7.12
Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol (2001) 5.80
Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol Cell Biol (1998) 5.01
Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity (1996) 3.66
An extended family of protein-tyrosine kinase genes differentially expressed in the vertebrate nervous system. Neuron (1991) 2.47
Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem (2004) 2.17
Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell (2011) 2.04
Therapeutic targeting of EPH receptors and their ligands. Nat Rev Drug Discov (2014) 1.74
Signaling network of the Btk family kinases. Oncogene (2000) 1.58
Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis. Microsc Res Tech (2002) 1.51
EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme. Cancer Cell (2013) 1.44
Ephrin-A5 induces rounding, blebbing and de-adhesion of EphA3-expressing 293T and melanoma cells by CrkII and Rho-mediated signalling. J Cell Sci (2002) 1.38
PI3K and STAT3: a new alliance. Cancer Discov (2011) 1.31
Identification and functional analysis of phosphorylated tyrosine residues within EphA2 receptor tyrosine kinase. J Biol Chem (2008) 1.24
Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis. J Thorac Oncol (2014) 1.19
The Eph family receptors and ligands. Pharmacol Ther (1998) 1.18
Five novel avian Eph-related tyrosine kinases are differentially expressed. Oncogene (1993) 1.17
The regulation of class IA PI 3-kinases by inter-subunit interactions. Curr Top Microbiol Immunol (2010) 1.16
Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer. J Clin Pathol (2014) 1.12
A critical role for the EphA3 receptor tyrosine kinase in heart development. Dev Biol (2006) 1.09
Activation of nonreceptor tyrosine kinase Bmx/Etk mediated by phosphoinositide 3-kinase, epidermal growth factor receptor, and ErbB3 in prostate cancer cells. J Biol Chem (2007) 1.08
Dual inhibition of EGFR and mTOR pathways in small cell lung cancer. Br J Cancer (2010) 1.06
Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules. Cancer Res (2000) 1.05
Effects of cancer-associated EPHA3 mutations on lung cancer. J Natl Cancer Inst (2012) 1.02
Regulation of class IA PI3Ks. Biochem Soc Trans (2007) 1.02
AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001. Clin Cancer Res (2009) 1.02
Cancer somatic mutations disrupt functions of the EphA3 receptor tyrosine kinase through multiple mechanisms. Biochemistry (2012) 1.01
Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma. J Clin Pathol (2011) 1.00
Essential role of Stat3 in PI3K-induced oncogenic transformation. Proc Natl Acad Sci U S A (2011) 0.98
Chemotherapy for small cell lung cancer. Semin Oncol (2003) 0.95
Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy. Eur J Med Chem (2013) 0.94
Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment. Cancer Res (2014) 0.93
Tyrosine kinase BMX phosphorylates phosphotyrosine-primed motif mediating the activation of multiple receptor tyrosine kinases. Sci Signal (2013) 0.88
BMX acts downstream of PI3K to promote colorectal cancer cell survival and pathway inhibition sensitizes to the BH3 mimetic ABT-737. Neoplasia (2014) 0.85
Caveolin-1 silencing arrests the proliferation of metastatic lung cancer cells through the inhibition of STAT3 signaling. Cell Signal (2012) 0.85
Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway. Mol Cancer (2015) 0.85
A high-content cellular senescence screen identifies candidate tumor suppressors, including EPHA3. Cell Cycle (2013) 0.85
Is stimulation of class-1 phosphatidylinositol 3-kinase activity by insulin sufficient to activate pathways involved in glucose metabolism. Biochem Soc Trans (1997) 0.83
Alternating chemotherapy with amrubicin plus cisplatin and weekly administration of irinotecan plus cisplatin for extensive-stage small cell lung cancer. Anticancer Res (2013) 0.83
High EphA3 expressing ophthalmic trigeminal sensory axons are sensitive to ephrin-A5-Fc: implications for lobe specific axon guidance. Neuroscience (2005) 0.83
IL-26 promotes the proliferation and survival of human gastric cancer cells by regulating the balance of STAT1 and STAT3 activation. PLoS One (2013) 0.82
Comparative integromics on Eph family. Int J Oncol (2006) 0.82
High levels of EphA3 expression are associated with high invasive capacity and poor overall survival in hepatocellular carcinoma. Oncol Rep (2013) 0.82
BMX promotes dual phosphorylation of tyrosine kinases. Cancer Discov (2013) 0.77
The putative tumor suppressor gene EphA3 fails to demonstrate a crucial role in murine lung tumorigenesis or morphogenesis. Dis Model Mech (2015) 0.76
Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer. Am J Clin Oncol (2015) 0.76
Safety and efficacy of platinum agents plus etoposide for patients with small cell lung cancer with interstitial lung disease. Anticancer Res (2013) 0.76
Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer. BMC Cancer (2015) 0.76